vs
Side-by-side financial comparison of CIVISTA BANCSHARES, INC. (CIVB) and IOVANCE BIOTHERAPEUTICS, INC. (IOVA). Click either name above to swap in a different company.
IOVANCE BIOTHERAPEUTICS, INC. is the larger business by last-quarter revenue ($86.8M vs $47.3M, roughly 1.8× CIVISTA BANCSHARES, INC.). Over the past eight quarters, IOVANCE BIOTHERAPEUTICS, INC.'s revenue compounded faster (1001.6% CAGR vs 11.3%).
Civista Bancshares, Inc. is a US-based bank holding company operating primarily across the Midwest region. It provides a full suite of personal and commercial banking services including deposit accounts, mortgage, consumer and commercial lending products, as well as wealth management solutions, serving retail consumers, small and medium-sized local businesses and community client segments.
Iovance Biotherapeutics, Inc. is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte (TIL) therapies against cancer.
CIVB vs IOVA — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $47.3M | $86.8M |
| Net Profit | $15.0M | — |
| Gross Margin | — | 67.4% |
| Operating Margin | — | -84.7% |
| Net Margin | 31.7% | — |
| Revenue YoY | — | 17.7% |
| Net Profit YoY | 47.4% | — |
| EPS (diluted) | $0.72 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $47.3M | — | ||
| Q4 25 | $46.3M | $86.8M | ||
| Q3 25 | $44.2M | $67.5M | ||
| Q2 25 | $41.4M | $60.0M | ||
| Q1 25 | $40.6M | $49.3M | ||
| Q4 24 | $40.4M | $73.7M | ||
| Q3 24 | $39.3M | $58.6M | ||
| Q2 24 | $38.1M | $31.1M |
| Q1 26 | $15.0M | — | ||
| Q4 25 | — | — | ||
| Q3 25 | $12.8M | $-91.3M | ||
| Q2 25 | $11.0M | $-111.7M | ||
| Q1 25 | $10.2M | $-116.2M | ||
| Q4 24 | — | — | ||
| Q3 24 | $8.4M | $-83.5M | ||
| Q2 24 | $7.1M | $-97.1M |
| Q1 26 | — | — | ||
| Q4 25 | — | 67.4% | ||
| Q3 25 | — | 43.0% | ||
| Q2 25 | — | 5.5% | ||
| Q1 25 | — | -0.8% | ||
| Q4 24 | — | 68.7% | ||
| Q3 24 | — | 46.2% | ||
| Q2 24 | — | -0.8% |
| Q1 26 | — | — | ||
| Q4 25 | 31.8% | -84.7% | ||
| Q3 25 | 35.4% | -140.7% | ||
| Q2 25 | 31.1% | -189.8% | ||
| Q1 25 | 29.4% | -245.8% | ||
| Q4 24 | 28.2% | -117.5% | ||
| Q3 24 | 25.2% | -152.1% | ||
| Q2 24 | 21.2% | -327.6% |
| Q1 26 | 31.7% | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 28.9% | -135.3% | ||
| Q2 25 | 26.6% | -186.2% | ||
| Q1 25 | 25.0% | -235.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | 21.3% | -142.7% | ||
| Q2 24 | 18.5% | -312.2% |
| Q1 26 | $0.72 | — | ||
| Q4 25 | $0.59 | — | ||
| Q3 25 | $0.68 | — | ||
| Q2 25 | $0.71 | $-0.33 | ||
| Q1 25 | $0.66 | $-0.36 | ||
| Q4 24 | $0.62 | $-0.24 | ||
| Q3 24 | $0.53 | $-0.28 | ||
| Q2 24 | $0.45 | $-0.34 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $297.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $553.9M | $698.6M |
| Total Assets | $4.3B | $913.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | $297.0M | ||
| Q3 25 | — | $300.8M | ||
| Q2 25 | — | $301.2M | ||
| Q1 25 | — | $359.7M | ||
| Q4 24 | — | $323.8M | ||
| Q3 24 | — | $397.5M | ||
| Q2 24 | — | $412.5M |
| Q1 26 | $553.9M | — | ||
| Q4 25 | $543.5M | $698.6M | ||
| Q3 25 | $499.0M | $702.3M | ||
| Q2 25 | $404.1M | $698.5M | ||
| Q1 25 | $397.4M | $767.9M | ||
| Q4 24 | $388.5M | $710.4M | ||
| Q3 24 | $394.4M | $773.5M | ||
| Q2 24 | $373.8M | $768.5M |
| Q1 26 | $4.3B | — | ||
| Q4 25 | $4.3B | $913.2M | ||
| Q3 25 | $4.1B | $904.9M | ||
| Q2 25 | $4.2B | $907.4M | ||
| Q1 25 | $4.1B | $966.7M | ||
| Q4 24 | $4.1B | $910.4M | ||
| Q3 24 | $4.1B | $991.1M | ||
| Q2 24 | $4.0B | $964.3M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-52.6M |
| Free Cash FlowOCF − Capex | — | $-61.9M |
| FCF MarginFCF / Revenue | — | -71.3% |
| Capex IntensityCapex / Revenue | — | 10.7% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-336.2M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $43.3M | $-52.6M | ||
| Q3 25 | $19.0M | $-78.7M | ||
| Q2 25 | $11.1M | $-67.4M | ||
| Q1 25 | $3.6M | $-103.7M | ||
| Q4 24 | $48.2M | $-73.3M | ||
| Q3 24 | $12.9M | $-59.0M | ||
| Q2 24 | $12.2M | $-98.4M |
| Q1 26 | — | — | ||
| Q4 25 | $42.1M | $-61.9M | ||
| Q3 25 | — | $-89.5M | ||
| Q2 25 | — | $-74.9M | ||
| Q1 25 | $3.5M | $-109.9M | ||
| Q4 24 | $44.1M | $-77.5M | ||
| Q3 24 | — | $-61.3M | ||
| Q2 24 | — | $-98.9M |
| Q1 26 | — | — | ||
| Q4 25 | 90.9% | -71.3% | ||
| Q3 25 | — | -132.7% | ||
| Q2 25 | — | -124.9% | ||
| Q1 25 | 8.5% | -222.8% | ||
| Q4 24 | 109.1% | -105.1% | ||
| Q3 24 | — | -104.6% | ||
| Q2 24 | — | -317.9% |
| Q1 26 | — | — | ||
| Q4 25 | 2.5% | 10.7% | ||
| Q3 25 | — | 16.1% | ||
| Q2 25 | — | 12.4% | ||
| Q1 25 | 0.4% | 12.6% | ||
| Q4 24 | 10.4% | 5.7% | ||
| Q3 24 | — | 3.9% | ||
| Q2 24 | — | 1.4% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 1.49× | — | ||
| Q2 25 | 1.01× | — | ||
| Q1 25 | 0.36× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.54× | — | ||
| Q2 24 | 1.73× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CIVB
| Net Interest Income | $37.8M | 80% |
| Noninterest Income | $9.4M | 20% |
IOVA
| Amtagvi | $64.9M | 75% |
| Proleukin | $21.9M | 25% |
